Phase 1b safety and antitumor activity of PLM60 (pegylated liposomal mitoxantrone) in NHL

Authors :: Sheng Hao
Zhangying Feng
Kun Lou
Simon Li
Li Chunlei
Mingxia Wang
Ronald Walls
Vivien Shi
Yueyin Peng
Chen Shan
Luana Pesco Koplowitz
Jing Yuan
Guangyu Ma
Yuhuan Gao
Source :: Journal of Clinical Oncology. 36:e19503-e19503
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e19503Background: PLM60 is a novel liposomal pegylated nanoparticle formulation of conventional mitoxantrone (cMI) that showed improved PK properties, good tolerability, and potential efficacy vers...

Subjects :: Antitumor activity
Cancer Research
Mitoxantrone
Liposome
Oncology
Tolerability
business.industry
Phase (matter)
medicine
Pharmacology
business
medicine.drug

Full Text Access

Tools